Antibody–drug conjugates (ADC) are targeted therapies that are designed to deliver highly potent cytotoxic agents to specific tumor cells saving normal tissue. They combined a monoclonal antibody (mAbs directed against a specific antigen) to a cytotoxic drug. ADCs are rapidly advancing and have shown promising results in cancer treatment. Prof Pruneri, Full Professor of Pathology at the University of Milan and Chair of the Department of Advanced Diagnostics (Milan National Cancer Institute), will share the state of the art of ADC use in cancer treatment, sharing considerations from a pathologist point of view in terms of the importance of biomarker selection and on-target, off-tumour toxicity (OTOT).

Webinar agenda

This webinar will cover:

• ADC action 
• State of the art in biomarker selection